ArticleEndocrinology2013
ERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female mice.
Article in Endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Small molecule conjugates with selective estrogen receptorActa pharmaceutica Sinica. B · 2024Article
- Interaction of estradiol and renin-angiotensin system with microRNAs-21 and -29 in renal fibrosis: focus on TGF-β/smad signaling pathway.Molecular biology reports · 2024Review
- Estrogenic bias in T-Lymphocyte biology: Implications for cardiovascular disease.Pharmacological research · 2021Review
- Computational models of cardiac hypertrophy.Progress in biophysics and molecular biology · 2021Review
- Connecting sex differences, estrogen signaling, and microRNAs in cardiac fibrosis.Journal of molecular medicine (Berlin, Germany) · 2019Review
- Female Heart Health: Is GPER the Missing Link?Frontiers in endocrinology · 2019Review
- Estrogen receptor beta maintains expression of KLF15 to prevent cardiac myocyte hypertrophy in female rodents.Molecular and cellular endocrinology · 2018Article
- The Association of Estrogen Receptor-β Gene Variation With Salt-Sensitive Blood Pressure.The Journal of clinical endocrinology and metabolism · 2017Article
- An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors.Experimental biology and medicine (Maywood, N.J.) · 2017Article
- Pharmacologic activation of estrogen receptor β increases mitochondrial function, energy expenditure, and brown adipose tissue.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function.Endocrinology · 2014Article
- Extranuclear estrogen receptor's roles in physiology: lessons from mouse models.American journal of physiology. Endocrinology and metabolism · 2014Article
- Translating extranuclear steroid receptor signaling to clinical medicine.Hormones & cancer · 2014Review
- Estrogen regulates histone deacetylases to prevent cardiac hypertrophy.Molecular biology of the cell · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Cardiac hypertrophy in humans can progress to cardiac failure if the underlying impetus is poorly controlled. An important direct stimulator of hypertrophy and its progression is the angiotensin II (AngII) peptide. AngII also causes hypertension that indirectly contributes to cardiac hypertrophy. Others and we have shown that estrogens acting through the estrogen receptor (ER)-β can inhibit AngII-induced or other forms of cardiac hypertrophy in mice. However, the proliferative effects of estrogen in breast and uterus that promote the development of malignancy preclude using the steroid to prevent cardiac disease progression. We therefore tested whether an ERβ selective agonist, β-LGND2, can prevent hypertension and cardiac pathology in female mice. AngII infusion over 3 weeks significantly stimulated systolic and diastolic hypertension, cardiac hypertrophy, and cardiac fibrosis, all significantly prevented by β-LGND2 in wild-type but not in ERβ genetically deleted mice. AngII stimulated the Akt kinase to phosphorylate and inhibit the glycogen synthase kinase-3β kinase, leading to GATA4 transcription factor activation and hypertrophic mRNA expression. As a novel mechanism, all these actions were opposed by estradiol and β-LGND2. Our findings provide additional understanding of the antihypertrophic effects of ERβ and serve as an impetus to test specific receptor agonists in humans to prevent the worsening of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.